Monitor early Auvelity Alzheimer's agitation adoption data (NBRx trends, prescriber activation) over the next 2-3 quarters for sustained growth signal. Watch for topline ENGAGE (BED) results in Q4 2026 and AXS-12 PDUFA in May 2027 as key pipeline catalysts. The stock's poor 22% T+20 win rate among prior calls suggests limited short-term price response to this in-line report.
Price Chart
Executive Summary
Axsome Therapeutics reported Q2 2026 total net product revenue of $218.4M (+46% YoY), driven by AUVELITY ($180.3M, +51% YoY) and SUNOSI ($35.8M, +20% YoY). The net loss widened to $51.3M (-$0.99 EPS) from $48.0M (-$0.97 EPS) a year ago, as SG&A surged 60% to $208.1M due to the Alzheimer's agitation launch and sales force expansion. The company has no guidance change, but early Auvelity Alzheimer's launch data (126% NBRx increase in 65+ patients) and AXS-12 PDUFA date (May 1, 2027) are positive pipeline catalysts. Despite revenue growth, expanding losses and rising costs keep the sentiment neutral.
Key Financial Metrics
Key Facts
- Q2 2026 total net product revenue $218.4M, +46% YoY from $150.0M
- AUVELITY net sales $180.3M (+51% YoY); 266,000 total prescriptions (+34% YoY, +12% QoQ)
- SUNOSI net revenue $35.8M (+20% YoY); ~61,000 prescriptions (+14% YoY, +8% QoQ)
- SYMBRAVO net sales $2.3M (461% YoY growth from low base); ~23,500 prescriptions
- Net loss $51.3M (-$0.99/share) vs $48.0M (-$0.97/share) YoY; includes $27.1M stock-based compensation
- SG&A expenses $208.1M, +60% YoY, driven by Alzheimer's launch activities and SYMBRAVO commercialization
- Cash $319.9M at June 30, 2026, down from $322.9M at Dec 31, 2025
- AUVELITY launched for Alzheimer's agitation in June 2026; NBRx 65+ patients up 126% in first 8 weeks
- AXS-12 NDA for narcolepsy cataplexy accepted; PDUFA May 1, 2027
- FOCUS-2 and FOCUS-3 pediatric ADHD Phase 3 trials for solriamfetol initiated
- No change to financial guidance; cash expected to fund operations into cash flow positivity
- Shares outstanding 52,299,889 at June 30, 2026
Financial Impact
Revenue growth of $68.4M YoY (+46%) driven by Auvelity and Sunosi; net loss widened by $3.3M; cash burn $3.0M in H1 2026
Risk Factors
- SG&A spend continues to outpace revenue growth (60% vs 46%); profitability timeline uncertain
- Auvelity Alzheimer's agitation launch is early; sustained demand growth not yet confirmed
- No specific numerical guidance provided; reliance on vague 'cash flow positivity' target
- Competitive pipeline risk from existing CNS drugs and other late-stage entrants
- Dilution from 1.4M share increase since end of 2025 (option exercises, equity issuances)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341206 |
| Document: axsm-20260810.htm | 0001193125-26-341206 |
| Document: axsm-ex99_2.htm | 0001193125-26-341206 |
| Document: 0001193125-26-341206-index-headers.html | 0001193125-26-341206 |
| Document: 0001193125-26-341206-index.html | 0001193125-26-341206 |
| Document: 0001193125-26-341206.txt | 0001193125-26-341206 |
| 8-K Data (Synthetic) | 0001193125-26-341206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access